{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:06:59Z","timestamp":1791864419955,"version":"4.3.4"},"reference-count":82,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Glycopeptides, such as vancomycin and teicoplanin, are primarily used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, such as cellulitis, endocarditis, meningitis, pneumonia, and septicemia, and are some of the most commonly prescribed parenteral antimicrobials. Parenteral glycopeptides are first-line therapy for severe MRSA infections; however, oral vancomycin is used as a first-line treatment of Clostridioides difficile infections. Also, we currently have the longer-acting lipoglycopeptides, such as dalbavancin, oritavancin, and telavancin to our armamentarium for the treatment of MRSA infections. Lastly, vancomycin is often used as an alternative treatment for patients with \u03b2-lactam hypersensitivity. Common adverse effects associated with glycopeptide use include nephrotoxicity, ototoxicity, and Redman Syndrome (RMS). The RMS is often mistaken for a true allergy; however, it is a histamine-related infusion reaction rather than a true immunoglobulin E (IgE)-mediated allergic reaction. Although hypersensitivity to glycopeptides is rare, both immune-mediated and delayed reactions have been reported in the literature. We describe the various types of glycopeptide hypersensitivity reactions associated with glycopeptides and lipoglycopeptides, including IgE-mediated reactions, RMS, and linear immunoglobulin A bullous dermatosis, as well as describe cross-reactivity with other glycopeptides.<\/jats:p>","DOI":"10.3390\/pharmacy8020070","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T04:15:13Z","timestamp":1587528913000},"page":"70","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Glycopeptide Hypersensitivity and Adverse Reactions"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-3554","authenticated-orcid":false,"given":"Vanthida","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Midwestern University College of Pharmacy-Glendale, Glendale, AZ 85308, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.","family":"Clayton","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, UC Davis Health, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly H.","family":"Welker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Mercy Gilbert Medical Center, Dignity Health, Gilbert, AZ 85297, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: Back to the future","volume":"67","author":"Butler","year":"2014","journal-title":"J. Antibiot."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: A history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/SMJ.0b013e3181647037","article-title":"Vancomycin: Understanding its past and preserving its future","volume":"101","author":"Levine","year":"2008","journal-title":"South Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.clinthera.2015.11.007","article-title":"Beyond Vancomycin: The Tail of the Lipoglycopeptides","volume":"37","author":"Klinker","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: A comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-Acting Lipoglycopeptides: \u201cLineless Antibiotics\u201d for Serious Infections in Persons Who Use Drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200003093421007","article-title":"Vancomycin-resistant enterococcal infections","volume":"342","author":"Murray","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/317542","article-title":"Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know","volume":"32","author":"Fridkin","year":"2001","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1128\/AAC.36.6.1204","article-title":"Absence of \u201cred man syndrome\u201d in patients being treated with vancomycin or high-dose teicoplanin","volume":"36","author":"Rybak","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0030-6665(20)30769-6","article-title":"Ototoxicity of vancomycin and analogues","volume":"26","author":"Brummett","year":"1993","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7326\/0003-4819-95-4-458","article-title":"Vancomycin Ototoxicity in patient with normal renal function","volume":"95","author":"Traber","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1001\/archinte.1988.00380100037008","article-title":"Acute interstitial nephritis associated with vancomycin therapy","volume":"148","author":"Bergman","year":"1988","journal-title":"Arch. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"Rybak","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The Whole Price of Vancomycin: Toxicities, Troughs, and Time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40264-016-0469-y","article-title":"Vancomycin-Induced Thrombocytopenia: A Narrative Review","volume":"40","author":"Mohammadi","year":"2017","journal-title":"Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gerstein, W., Colombo, E., and Harji, F. (2018). Documented vancomycin-induced severe immune-mediated thrombocytopaenia. BMJ Case Rep., 2018.","DOI":"10.1136\/bcr-2018-224682"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.anai.2016.03.030","article-title":"Immune-mediated reactions to vancomycin: A systematic case review and analysis","volume":"116","author":"Minhas","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1385\/CRIAI:24:3:221","article-title":"Hypersensitivity reactions to non-beta-lactam antibiotics","volume":"24","author":"Tilles","year":"2003","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1592\/phco.25.2.308.56953","article-title":"Probable vancomycin-associated toxic epidermal necrolysis","volume":"25","author":"Craycraft","year":"2005","journal-title":"Pharmacotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/bjd.12720","article-title":"A case of vancomycin-associated linear IgA bullous dermatosis and IgA antibodies to the alpha3 subunit of laminin-332","volume":"170","author":"Zenke","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.jaci.2009.12.981","article-title":"Anaphylaxis","volume":"125","author":"Simons","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000353584","article-title":"Linear IgA bullous disease presenting as toxic epidermal necrolysis: A case report and review of the literature","volume":"227","author":"Kakar","year":"2013","journal-title":"Dermatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2019.02.002","article-title":"Vancomycin-associated drug-induced hypersensitivity syndrome","volume":"81","author":"Madigan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/157.3.502","article-title":"Vancomycin and the red-man syndrome: Pharmacodynamics of histamine release","volume":"157","author":"Polk","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1081-1206(10)62416-7","article-title":"Vancomycin anaphylaxis and successful desensitization in a patient with end stage renal disease on hemodialysis by maintaining steady antibiotic levels","volume":"84","author":"Chopra","year":"2000","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_30","first-page":"402","article-title":"Vancomycin anaphylaxis and successful desensitization","volume":"73","author":"Anne","year":"1994","journal-title":"Ann. Allergy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00045391-200007050-00010","article-title":"Vancomycin anaphylaxis in a patient with vancomycin-induced red man syndrome","volume":"7","author":"Hassaballa","year":"2000","journal-title":"Am. J. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/00365549209061350","article-title":"IgE-mediated reaction to vancomycin and teicoplanin after treatment with vancomycin","volume":"24","author":"Knudsen","year":"1992","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/infdis\/158.6.1413","article-title":"Severe reaction to vancomycin not mediated by histamine release and documented by rechallenge","volume":"158","author":"Sahai","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaip.2015.06.017","article-title":"A role for vancomycin epicutaneous skin testing in the evaluation of perioperative anaphylaxis","volume":"3","author":"Otani","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.krcp.2014.09.005","article-title":"Immunoglobulin E-mediated hypersensitivity reaction after intraperitoneal administration of vancomycin","volume":"34","author":"Hwang","year":"2015","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/01.ccm.0000551324.52923.88","article-title":"Oral Vancomycin desensitization in a critically ill patient with allergic reaction","volume":"47","author":"Laehn","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0897190016668437","article-title":"Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function","volume":"30","author":"Baumgartner","year":"2017","journal-title":"J. Pharm. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s15010-012-0328-4","article-title":"Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection","volume":"41","author":"Bosse","year":"2013","journal-title":"Infection"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1939-4551-6-16","article-title":"Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient","volume":"6","author":"Mahabir","year":"2013","journal-title":"World Allergy Organ. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1345\/aph.17411","article-title":"Successful vancomycin desensitization in a patient with end-stage renal disease and anaphylactic shock to vancomycin","volume":"32","author":"Sorensen","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1001\/archinte.1990.00390210145031","article-title":"Desensitization in the management of vancomycin hypersensitivity","volume":"150","author":"Lin","year":"1990","journal-title":"Arch. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-100-1-157_1","article-title":"Desensitization to vancomycin","volume":"100","author":"Lerner","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/ai.1994.v94.a55251","article-title":"Vancomycin hypersensitivity: Synergism with narcotics and \u201cdesensitization\u201d by a rapid continuous intravenous protocol","volume":"94","author":"Wong","year":"1994","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0091-6749(97)70287-2","article-title":"Acute cardiac and pulmonary arrest after infusion of vancomycin with subsequent desensitization","volume":"100","author":"Villavicencio","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2169\/internalmedicine.45.1388","article-title":"Successful vancomycin desensitization with a combination of rapid and slow infusion methods","volume":"45","author":"Kitazawa","year":"2006","journal-title":"Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1345\/aph.1A002","article-title":"Desensitization protocols for vancomycin hypersensitivity","volume":"35","author":"Wazny","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/cid\/cit949","article-title":"Antibiotic hypersensitivity reactions and approaches to desensitization","volume":"58","author":"Legendre","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bcp.13827","article-title":"Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases","volume":"85","author":"Garel","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/cup.12742","article-title":"False-negative direct immunofluorescence testing in vancomycin-induced linear IgA bullous dermatosis: A diagnostic pitfall","volume":"43","author":"Winn","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2500\/aap.2012.33.3498","article-title":"The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"33","author":"Blumenthal","year":"2012","journal-title":"Allergy Asthma Proc."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chamorro-Pareja, N., Patel, A., Youngberg, G., and Gonzalez-Estrada, A. (2018). Case of drug reaction with eosinophilia and systemic symptoms secondary to vancomycin. BMJ Case Rep., 2018.","DOI":"10.1136\/bcr-2018-227378"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Webb, P.S., and Al-Mohammad, A. (2016). Enigma: Infection or allergy? Vancomycin-induced DRESS syndrome with dialysis-dependent renal failure and cardiac arrest. BMJ Case Rep., 2016.","DOI":"10.1136\/bcr-2016-215911"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaci.2019.04.009","article-title":"HLA- and immune-mediated adverse drug reactions: Another hit with vancomycin","volume":"144","author":"Pirmohamed","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/j.1875-9114.1997.tb03104.x","article-title":"Delayed hypersensitivity reaction to vancomycin","volume":"17","author":"Marik","year":"1997","journal-title":"Pharmacotherapy"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wilcox, O., Hassanein, M., Armstrong, J., and Kassis, N. (2017). Case report: Atypical presentation of vancomycin induced DRESS syndrome: A case report and review of the literature. BMC Pulm. Med., 17.","DOI":"10.1186\/s12890-017-0564-6"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Guner, M.D., Tuncbilek, S., Akan, B., and Caliskan-Kartal, A. (2015). Two cases with HSS\/DRESS syndrome developing after prosthetic joint surgery: Does vancomycin-laden bone cement play a role in this syndrome?. BMJ Case Rep., 2015.","DOI":"10.1136\/bcr-2014-207028"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/0003-4819-95-5-658_1","article-title":"Vancomycin and interstitial nephritis","volume":"95","author":"Eisenberg","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0002-9343(88)90287-2","article-title":"Vancomycin-induced interstitial nephritis","volume":"84","author":"Ratner","year":"1988","journal-title":"Am. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1345\/aph.17448","article-title":"Vancomycin-induced acute interstitial nephritis","volume":"32","author":"Wai","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1523-1755.2001.060002804.x","article-title":"Drug-induced acute interstitial nephritis","volume":"60","author":"Rossert","year":"2001","journal-title":"Kidney Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1592\/phco.27.10.1456","article-title":"Acute interstitial nephritis associated with coadministration of vancomycin and ceftriaxone: Case series and review of the literature","volume":"27","author":"Plakogiannis","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/08860229809045178","article-title":"Drug-induced acute interstitial nephritis","volume":"20","author":"Alexopoulos","year":"1998","journal-title":"Ren. Fail."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s10157-011-0559-1","article-title":"Biopsy-proven vancomycin-associated interstitial nephritis and acute tubular necrosis","volume":"16","author":"Htike","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MAJ.0b013e3180a6ec1e","article-title":"Vancomycin-induced acute granulomatous interstitial nephritis: Therapeutic options","volume":"334","author":"Hong","year":"2007","journal-title":"Am. J. Med. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/27.suppl_B.17","article-title":"Anaphylactoid reactions to glycopeptide antibiotics","volume":"27","author":"Polk","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003495-200464090-00001","article-title":"Glycopeptide antibiotics: From conventional molecules to new derivatives","volume":"64","author":"Courvalin","year":"2004","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jclinane.2009.01.007","article-title":"Stridor accompanying red man\u2019s syndrome following perioperative administration of vancomycin","volume":"21","author":"Apuya","year":"2009","journal-title":"J. Clin. Anesth."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: Systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jac\/28.3.476","article-title":"Allergic cross-reaction of teicoplanin and vancomycin","volume":"28","author":"Grek","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2710.2011.01291.x","article-title":"High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy","volume":"37","author":"Hsiao","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0163-4453(98)91077-5","article-title":"Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin","volume":"37","author":"Marshall","year":"1998","journal-title":"J. Infect."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/jcpt.12159","article-title":"Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin","volume":"39","author":"Yang","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3904\/kjim.2013.28.6.678","article-title":"Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: A prospective observational study","volume":"28","author":"Ok","year":"2013","journal-title":"Korean J. Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.jcf.2018.08.003","article-title":"Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series","volume":"17","author":"Bernstein","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"O730","DOI":"10.1111\/1469-0691.12498","article-title":"hVISA and MRSA endocarditis: An 8-year experience in a tertiary care centre","volume":"20","author":"Maor","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jgs.12634","article-title":"Effect of nosocomial bloodstream infections on mortality, length of stay, and hospital costs in older adults","volume":"62","author":"Kaye","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/526772","article-title":"Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic","volume":"46","author":"Billeter","year":"2008","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_82","unstructured":"(2018). Dalvance (Dalbavancin) [Package Insert], Allergan USA, Inc."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/8\/2\/70\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:21:36Z","timestamp":1760361696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/8\/2\/70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["pharmacy8020070"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy8020070","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]}}}